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Osteoporosis results from an imbalance between bone resorption and bone formation.While bone resorption
inhibitors are widely used to treat osteoporosis, stimulating bone formation is more challenging. Recently,
McClung et al. (2014) found that neutralization of sclerostin, a potent inhibitor of bone formation, effectively
increased bone mass in postmenopausal women.Osteocytes, the most abundant cell type
in the mammalian bone, are considered
to have essential homeostatic functions.
While entirely surrounded by mineralized
tissue, these cells are interconnected
by a dense network of bone channels.
Osteocytes are the major source of
receptor activator of NF-kB ligand
(RANKL), an essential cytokine respon-
sible for osteoclast activation and bone
resorption, and specifically produce
large amounts of sclerostin, one of the
most potent inhibitors of bone formation
in the body, making it an interesting
target for treatment of bone disease in
humans. As a key step in treating low
bone density clinically while avoiding
the side effects of RANKL inhibition, a
recently conducted phase 2 trial showed
that neutralization of sclerostin with a
humanized monoclonal antibody (romo-
suzumab) significantly improved bone
mineral density in osteoporotic women
(McClung et al., 2014).
Sclerostin is the product of the SOST
gene, which was found by geneticists
in 2001 to be mutated in a few descen-
dants of Dutch settlers in South Africa
with excessively high bone mass (sclero-
stosis) (Balemans et al., 2001). Altered
regulation of SOST was also found in a
very similar syndrome of high bone
mass, termed van Buchem disease,
which was virtually exclusively confined
to a few patients stemming from a small
village in the Netherlands (Staehling-
Hampton et al., 2002). The protein
product of SOST, sclerostin, effectively
controls bone formation by binding to
the low-density lipoprotein receptor 6
(LRP6). Wnt proteins, which are powerful
inducers of bone formation, bind to
LRP6, thereby fostering the differen-
tiation of mesenchymal precursor cells
into bone-forming osteoblasts. Sclerostin394 Cell Metabolism 20, September 2, 2014 ªinterferes with this interaction and there-
fore effectively blunts bone formation
(van Bezooijen et al., 2004). Although
the uncontrolled bone apposition in
the rare genetic absence of sclerostin
supports its homeostatic function in
the skeleton, dampening of sclerostin
may have a therapeutic value in con-
ditions of enhanced bone loss, such as
postmenopausal osteoporosis, tumor
metastasis, and inflammation-induced
bone loss. In particular, its virtually ex-
clusive expression in the bone tissue
makes sclerostin an appealing therapeu-
tic target.
That inhibition of sclerostin by neutral-
izing antibodies increases bone mass
was initially shown in ovariectomized
rats as well as in cynomologousmonkeys.
The first evidence that pharmacologic
inhibition of sclerostin affects human
bone came from a phase 1 study with
the anti-sclerostin antibody romosuzu-
mab (Padhi et al., 2011). A single dose of
this antibody increased bone formation
but decreased bone resorption markers.
The recently published phase 2 trial by
McClung et al. (2014) was larger, enrolling
419 postmenopausal women with low
bone mineral density (T scores between
2 and 3.5), and defined changes of
bone mineral density in the lumbar spine
after 12 months as its primary endpoint.
Dependent on the dose of romosuzumab
(70, 140, or 210 mg monthly; 140 or
210 mg every 3 months), bone mineral
density significantly increased between
5.4% and 11.3% in the lumbar spine
compared to placebo treatment. Further-
more, two additional nonblinded treat-
ment arms, with the bisphosphonate
alendronate and the parathyroid hormone
teriparatide, revealed that the lower
dosing regimens of the anti-sclerostin
antibody had comparable effects to2014 Elsevier Inc.alendronate and teriparatide on bone
mineral density. Only higher doses,
140 mg and 210 mg of romosuzumab
per month, increased bone mineral den-
sity beyond what was observed with
bisphosophoates and teriparatide.
These findings provide solid evidence
that inhibition of sclerostin is effective
in increasing bone mass in osteopenic
postmenopausal women. Analysis of
markers of bone metabolism revealed
a very rapid, but also transient, increase
of bone formation markers. Hence, scle-
rostin could resemble a natural brake for
bone formation, which, once neutralized,
allows rapid differentiation of mesen-
chymal cells into functional osteoblasts
(Figure 1). On the other hand, this anabolic
effect on bone appears to fade over time,
which may suggest that other natural
brake mechanisms inhibiting Wnt-medi-
ated bone formation, such as dickkopf-
1, may step in for sclerostin (Diarra et al.,
2007). Still, romosuzumab permits
increasing bone mass, which may be
additionally supported by decreasing
bone resorption markers. The remarkable
decrease of bone resorption after sclero-
stin inhibition may be explained by the
induction of osteprotegerin, a natural
inhibitor of RANKL, by the Wnt proteins
(Diarra et al., 2007) (Figure 1). Inhibition
of sclerostin would unchain Wnt sig-
naling, thereby increasing osteprotegerin
and suppressing RANKL-induced bone
resorption (Figure 1). The divergent
effects on bone formation and bone
resorption after sclerostin inhibition
are interesting, since some inhibitors,
such as bisphosphonates and denosu-
mab, suppress both processes, whereas
parathyroid hormone increases both
bone formation and bone resorption.
Nonetheless, direct comparisons be-
tween bisphopshonates, teriparatide,
Figure 1. Effect of the Anti-Sclerostin Antibody Romosuzumab on
the Bone
Osteocytes (blue) are embedded in the bone matrix (gray) and produce scle-
rostin as well as RANKL (orange). Sclerostin inhibits differentiation of bone-lin-
ing cells (red) into osteoblasts (green). Romosuzumab blocks sclerostin and
removes the brake on Wnt protein-dependent osteoblast differentiation (ar-
row). Wnt proteins also stimulate the expression of osteoprotegerin (OPG),
an inhibitor of RANKL, thereby blocking osteoclast-mediated bone resorption.
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biomarkers must be consid-
ered with caution, since no
blinding for these therapies
was performed in this study.
Although the data from this
phase 2 study are interesting,
several questions remain. For
instance, it is unclear whether
the transient changes in
markers of bone metabolism
will translate into a long-term
effect on bone mass and
fragility. Furthermore, the
long-term safety of sclerostin
inhibition remains to be
determined. Although even
the excessive new bone for-
mation observed in genetic
absence of sclerostin is not
associated with increased
tumor burden, this point re-mains to be determined during pharma-
cologic blockade of sclerostin. It is also
not yet known whether sclerostin inhibi-
tion may worsen joint fusion (ankylosis)
in the context of pathologic new bone for-
mation during inflammatory or degenera-
tive joint diseases (Heiland et al., 2012).
This issue appears to be important, since
aged individuals are the primary target
population of such treatment. Finally,
since factors that influence bone resorp-
tion (RANKL) (Kiechl et al., 2013) and
bone formation (osteocalcin) (Lee et al.,
2007) control hepatic insulin resistance,
and sclerostin levels are elevated in type
2 diabetes mellitus (Garcı´a-Martı´n et al.,2012), the potential effects of sclerostin
inhibition on insulin resistance and meta-
bolism would have to be defined.
In summary, romosuzumab, a neutral-
izing antibody against sclerostin, will
deepen our knowledge of the physio-
logical role of sclerostin in the human
skeleton and will additionally open new
possibilities to fight bone loss in humans,
which is a major challenge in the aging
population.REFERENCES
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